Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9591104 | 0.80 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| SCHEMBL5864500 | 0.79 | — | — | |
| SCHEMBL6560631 | 0.79 | — | — | |
| SCHEMBL2154133 | 0.78 | TSHR (0.38) | ALDH1A1TSHR | |
| SCHEMBL938172 | 0.78 | MEN1 (0.31) | — | |
| SCHEMBL16360622 | 0.77 | — | — | |
| SCHEMBL3923809 | 0.76 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL5710311 | 0.75 | PDK1 (0.39) | — | |
| SCHEMBL5737908 | 0.75 | PDK1 (0.39) | — | |
| SCHEMBL5737910 | 0.75 | PDK1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | SIRONAX LTD (KY) | 2024-10-29 | — | — | US | disclosed |
| WO-2024121395-A1 | IAP INHIBITORS, METHODS OF MAKING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL SA (CH) | 2024-06-13 | — | — | WO | disclosed |
| CN-111788184-B | Diaryl substituted 5, 5-fused ring compounds useful as C5aR inhibitors | 凯莫森特里克斯股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116987072-A | Compounds and uses thereof | 武汉呈瑞生物医药科技有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-113272272-B | RIP1 inhibitors | 圣瑞诺有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-111032658-B | 5-5 fused rings as C5a inhibitors | 凯莫森特里克斯股份有限公司 | 2022-12-20 | — | — | CN | disclosed |
| EP-3630774-B1 | 5-5 FUSED RINGS AS C5A INHIBITORS | CHEMOCENTRYX INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-11479553-B2 | 5-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20210353607-A1 | PI3K INHIBITORS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2021-11-18 | — | — | US | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010029082-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| US-4749414-A | CONTAINERS FOR INTEGRAL FLUID DELIVERY | THE DOW CHEMICAL COMPANY (US) | 1988-06-07 | — | — | US | disclosed |
| US-4664978-A | ADHERENT LAYER OF FLUORINE-CONTAINING CELLULOSE ETHER ESTER | THE DOW CHEMICAL COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479553-B2 | 5-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | ALDH1A1 3141/4885TSHR 825/4885 |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | ALDH1A1 2995/4885TSHR 654/4885 |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | ALDH1A1 2150/4885TSHR 1219/4885 |
| US-20100105711-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | ALDH1A1 1908/4885TSHR 4161/4885 |
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | RIPK1, RIPK3, RIPK4 | ALDH1A1 3794/4885TSHR 3349/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | ALDH1A1 1680/4885TSHR 4209/4885 |
| US-20210353607-A1 | PI3K INHIBITORS AND USES THEREOF | PIK3CA, AKT3, GSK3B | ALDH1A1 2009/4885TSHR 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.